Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 14, 2026
Allarity Therapeutics, Inc. (ALLR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $3.4 million. Free cash flow was -$2.6 million. As of Jun 30, 2026 it held $17.0 million in cash and investments and $20.9 million in total debt.
Revenue
$0
-100.0% vs prior quarter
Net income
$-3.40M
-46.8% vs year-ago quarter
Operating cash flow
$-2.56M
+53.2% vs year-ago quarter
Free cash flow
$-2.56M
+43.7% vs prior quarter
EPS
—
Dividend per share
None
Shares outstanding
15.91M
+8.8% vs year-ago quarter
Net cash
$-3.88M
Q2 FY2026
Operating margin
-10752.0%
Q1 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALLR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1860657
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $25,000 | — | — | — |
| Operating income | -$2.7M | -$2.7M | -$2.9M | -$2.5M | -$4.1M |
| Net income | -$3.4M | -$2.8M | -$3.4M | -$2.8M | -$2.3M |
| Operating cash flow | -$2.6M | -$4.5M | -$3.2M | -$3.4M | -$5.5M |
| Free cash flow | -$2.6M | -$4.6M | — | — | — |
| Total assets | $32.1M | $34.9M | $18.3M | $20.8M | $21.2M |
| Total liabilities | $28.6M | $28.0M | $8.4M | $8.8M | $9.0M |
| Stockholders' equity | $3.5M | $6.9M | $9.8M | $12.0M | $12.2M |
| Cash and investments | $17.0M | $19.8M | $14.7M | $16.9M | $17.8M |
| Total debt | $20.9M | $20.1M | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Nov 2, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Agreement ended
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 11, 2026 |
All 403 Allarity Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.